Treatment of Herpes simplex encephalitis with the helicase-primase inhibitor pritelivir in an immunocompromised patient
Authors:
Open Access
- 2 September 2026
- journal article
- case report
- Published by Springer Nature in npj Antimicrobials and Resistance
- Vol. 4 (1) , 56
Abstract
Pritelivir, a novel helicase-primase inhibitor, has successfully completed a global Phase 3 trial for refractory herpes simplex virus (HSV) infections in immunocompromised patients. This case report is the first clinical use of pritelivir in Herpes simplex encephalitis (HSE). An allogeneic hematopoietic cell transplant recipient developed HSE and was treated with acyclovir. After 1.5 months, while still on valacyclovir prophylaxis, HSE relapsed, confirmed by Magnetic Resonance Imaging (MRI) and HSV1 DNA detection in cerebrospinal fluid (CSF). Following transient response to acyclovir and foscarnet, combined pritelivir/acyclovir treatment was initiated in this comatose patient with cerebral edema and necrosis. Clinical improvement occurred with increased alertness and motor activity, enabling discharge to rehabilitation. MRI showed no further progression, and CSF HSV DNA load became undetectable. No relevant adverse effects were observed. Pritelivir plasma and CSF concentrations exceeded the 50% effective concentration for HSV1. This case highlights the potential of pritelivir for treating HSE.Keywords
This publication has 13 references indexed in Scilit:
- Pritelivir Demonstrated Superior Efficacy Compared to Investigator’s Choice Treatment for Refractory Herpes Simplex Virus Infections In Immunocompromised Patients: PRIOH-1, Phase 3 Safety and EfficacyTransplantation and Cellular Therapy, 2026
- How we diagnose and manage refractory and resistant herpes simplex virus mucocutaneous infection after haematopoietic cell transplantationClinical Microbiology and Infection, 2025
- Refractory and Resistant Herpes Simplex Virus Mucocutaneous Infections in Immunocompromised Patients: Literature Review and Proposed Definitions for Use in Clinical TrialsClinical Infectious Diseases, 2025
- Discovery, Chemistry, and Preclinical Development of Pritelivir, a Novel Treatment Option for Acyclovir-Resistant Herpes Simplex Virus InfectionsJournal of Medicinal Chemistry, 2022
- Efficacy of pritelivir and acyclovir in the treatment of herpes simplex virus infections in a mouse model of herpes simplex encephalitisAntiviral Research, 2018
- Baseline sensitivity of HSV-1 and HSV-2 clinical isolates and defined acyclovir-resistant strains to the helicase–primase inhibitor pritelivirAntiviral Research, 2013
- Herpes simplex virus encephalitis: new infection or reactivation?Current Opinion in Neurology, 2011
- Herpes Simplex Encephalitis in Sweden, 1990-2001: Incidence, Morbidity, and MortalityClinical Infectious Diseases, 2007
- Outcome of and Prognostic Factors for Herpes Simplex Encephalitis in Adult Patients: Results of a Multicenter StudyClinical Infectious Diseases, 2002
- Foscarnet penetrates the blood-brain barrier: rationale for therapy of cytomegalovirus encephalitisAntimicrobial Agents and Chemotherapy, 1993